Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD
NCT02763033Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2017
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised trial in graft-versus-host disease (GVHD) (2 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Incidence of grade II-IV Graft-Versus-Host Disease at Day 100. Started Apr 2017; status: completed.
02
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02763033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763033.